Plexxikon CEO and leadership

Dr. Bollag transitioned to a part-time role as chief biologist in July 2021, having served as chief executive officer since 2013.

Previously, he had served as senior vice president of research and vice president of discovery biology. Dr. Bollag joined Plexxikon in 2002, and was instrumental in the discovery and development of both Turalio and Zelboraf, Plexxikon’s FDA-approved drugs. Prior to Plexxikon, he helped build drug discovery capabilities at Syrrx, Inc., where he was the director of cellular pharmacology.

Before Syrrx, he held escalating positions at Onyx Pharmaceuticals, initially as one of the founding scientists and eventually senior director of small molecule therapeutics. While there, Dr. Bollag was involved in the Onyx collaboration with Bayer to discover BAY 43-9006 (Nexavar), now an approved cancer treatment.

Prior to Onyx, Dr. Bollag held various scientific positions at Cetus, Inc.

Dr. Bollag earned his Ph.D. in biochemistry from the University of California, Berkeley.

Jackie Walling MBChB Ph.D. is an experienced biotech pharma executive with expertise in global clinical development and strategy. She has more than 30 years of experience in developing new medicines for cancer patients and has contributed in various leadership roles to the approvals of widely used agents such as gemcitabine, pemetrexed, and talazoparib.